{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:37:54Z","timestamp":1768030674558,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Malaysian Government"},{"DOI":"10.13039\/501100000923","name":"Australian Research Council\u2019s Discovery Project","doi-asserted-by":"publisher","award":["DP120102778"],"award-info":[{"award-number":["DP120102778"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council\u2019s Discovery Project","doi-asserted-by":"publisher","award":["DPI150103953"],"award-info":[{"award-number":["DPI150103953"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council Centre of Research Excellence in Tuberculosis Control","doi-asserted-by":"publisher","award":["APP1043225"],"award-info":[{"award-number":["APP1043225"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council Centre of Research Excellence in Tuberculosis Control","doi-asserted-by":"publisher","award":["APP104434"],"award-info":[{"award-number":["APP104434"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NSW Government Infrastructure"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ejpb.2016.07.014","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T23:07:09Z","timestamp":1468624029000},"page":"205-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment"],"prefix":"10.1016","volume":"107","author":[{"given":"T.","family":"Parumasivam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.G.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.H.","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Triccas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.J.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2016.07.014_b0005","unstructured":"World Health Organization, Global Tuberculosis Report 2014, in, <http:\/\/www.who.int\/tb\/publications\/global_report\/gtbr14_main_text.pdf?ua=1>, 2013."},{"key":"10.1016\/j.ejpb.2016.07.014_b0010","unstructured":"World Health Organization, Treatment of Tuberculosis: Guidelines. fourth ed., 2010."},{"key":"10.1016\/j.ejpb.2016.07.014_b0015","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejpb.2016.07.014_b0020","first-page":"1","article-title":"New anti-tuberculosis drugs and regimens: 2015 update","volume":"1","author":"D\u2019Ambrosio","year":"2015","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.ejpb.2016.07.014_b0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(13)70328-1","article-title":"New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects","volume":"14","author":"Zumla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejpb.2016.07.014_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a021154","article-title":"The tuberculosis drug discovery and development pipeline and emerging drug targets","volume":"5","author":"Mdluli","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejpb.2016.07.014_b0035","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1192\/bjp.180.6.515","article-title":"Thioridazine and sudden unexplained death in psychiatric in-patients","volume":"180","author":"Reilly","year":"2002","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejpb.2016.07.014_b0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01564324","article-title":"Chlorpromazine (thorazine) for mental illness in the presence of pulmonary tuberculosis","volume":"30","author":"Pleasure","year":"1956","journal-title":"Psychiatr. Q"},{"key":"10.1016\/j.ejpb.2016.07.014_b0045","first-page":"521","article-title":"Studies on antituberculotic action of some phenothiazine derivatives in vitro","volume":"239","author":"Moln\u00e1r","year":"1977","journal-title":"Zentralbl Bakteriol Orig A"},{"key":"10.1016\/j.ejpb.2016.07.014_b0050","doi-asserted-by":"crossref","first-page":"e34538","DOI":"10.1371\/journal.pone.0034538","article-title":"Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis","volume":"7","author":"Machado","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2016.07.014_b0055","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.meegid.2011.08.009","article-title":"Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex","volume":"12","author":"Rodrigues","year":"2012","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.ejpb.2016.07.014_b0060","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/jac\/dkn070","article-title":"Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis","volume":"61","author":"Rodrigues","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2016.07.014_b0065","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/jac\/dkl500","article-title":"Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps","volume":"59","author":"Amaral","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2016.07.014_b0070","doi-asserted-by":"crossref","first-page":"928","DOI":"10.5455\/2319-2003.ijbcp20141207","article-title":"Thioridazine: a potential adjuvant in pharmacotherapy of drug resistant tuberculosis","volume":"3","author":"Kishore","year":"2014","journal-title":"Int. J. Basic Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.07.014_b0075","first-page":"267","article-title":"Mechanisms by which thioridazine in combination with antibiotics cures extensively drug-resistant infections of pulmonary tuberculosis","volume":"28","author":"Amaral","year":"2014","journal-title":"In Vivo"},{"key":"10.1016\/j.ejpb.2016.07.014_b0080","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1073\/pnas.0500469102","article-title":"Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs","volume":"102","author":"Weinstein","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2016.07.014_b0085","doi-asserted-by":"crossref","first-page":"11456","DOI":"10.1074\/jbc.M508844200","article-title":"Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2)","volume":"281","author":"Yano","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2016.07.014_b0090","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.tube.2014.09.002","article-title":"Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy","volume":"94","author":"de Knegt","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejpb.2016.07.014_b0095","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tube.2014.08.016","article-title":"Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis","volume":"94","author":"Singh","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejpb.2016.07.014_b0100","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijantimicag.2006.10.013","article-title":"In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis","volume":"29","author":"Martins","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejpb.2016.07.014_b0105","doi-asserted-by":"crossref","first-page":"e12640","DOI":"10.1371\/journal.pone.0012640","article-title":"The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis","volume":"5","author":"van Soolingen","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2016.07.014_b0110","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jac\/dkt037","article-title":"Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis","volume":"68","author":"Dutta","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2016.07.014_b0115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157489111796064614","article-title":"Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB","volume":"6","author":"Zarir","year":"2011","journal-title":"Recent Pat. Antiinfect. Drug Discov."},{"key":"10.1016\/j.ejpb.2016.07.014_b0120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/jac\/dkr500","article-title":"Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine","volume":"67","author":"Abbate","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2016.07.014_b0125","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1128\/AAC.02981-14","article-title":"Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis","volume":"58","author":"Dutta","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2016.07.014_b0130","first-page":"231","article-title":"Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine","volume":"26","author":"Amaral","year":"2012","journal-title":"In Vivo"},{"key":"10.1016\/j.ejpb.2016.07.014_b0135","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2125.2003.01893.x","article-title":"Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.07.014_b0140","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.07.014_b0145","first-page":"319","article-title":"Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder","volume":"43","author":"Chan","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejpb.2016.07.014_b0150","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/17425247.2014.877886","article-title":"An update on the use of rifapentine for tuberculosis therapy","volume":"11","author":"Chan","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2016.07.014_b0155","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1371\/journal.pmed.0040344","article-title":"Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model","volume":"4","author":"Rosenthal","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejpb.2016.07.014_b0160","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/jps.23911","article-title":"A novel inhalable form of rifapentine","volume":"103","author":"Chan","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.07.014_b0165","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2012.08.007","article-title":"A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics","volume":"83","author":"Chan","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.07.014_b0170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0731-7085(02)00097-3","article-title":"Simultaneous LC determination of some antidepressants combined with neuroleptics","volume":"29","author":"Karpinska","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2016.07.014_b0175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1086\/380413","article-title":"Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Gu\u00e9rin vaccine","volume":"189","author":"Pinto","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2016.07.014_b0180","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11095-013-1245-7","article-title":"A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection","volume":"31","author":"Chan","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.07.014_b0185","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1021\/acs.molpharmaceut.5b00833","article-title":"In vitro evaluation of inhalable verapamil-rifapentine particles for tuberculosis therapy","volume":"13","author":"Parumasivam","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.07.014_b0190","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1208\/s12248-013-9537-8","article-title":"Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection","volume":"16","author":"Zhou","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2016.07.014_b0195","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/10717544.2013.868555","article-title":"Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery","volume":"21","author":"Rattanupatam","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2016.07.014_b0200","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejps.2008.05.009","article-title":"Micro-particle corrugation, adhesion and inhalation aerosol efficiency","volume":"35","author":"Adi","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.07.014_b0205","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02346-12","article-title":"Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis","volume":"57","author":"Dharmadhikari","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2016.07.014_b0210","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1023\/A:1013082531394","article-title":"Use of solid corrugated particles to enhance powder aerosol performance","volume":"18","author":"Chew","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.07.014_b0215","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11095-004-9020-4","article-title":"How much particle surface corrugation is sufficient to improve aerosol performance of powders?","volume":"22","author":"Chew","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.07.014_b0220","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1021\/mp500586p","article-title":"Novel inhaled combination powder containing amorphous colistin and crystalline rifapentine with enhanced antimicrobial activities against planktonic cells and biofilm of Pseudomonas aeruginosa for respiratory infections","volume":"12","author":"Zhou","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.07.014_b0225","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1007\/s11095-008-9613-4","article-title":"Investigations on the humidity-induced transformations of salbutamol sulphate particles coated with l-leucine","volume":"25","author":"Raula","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.07.014_b0230","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejpb.2016.02.010","article-title":"l-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders","volume":"102","author":"Li","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.07.014_b0235","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1128\/AAC.03408-14","article-title":"Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis","volume":"58","author":"Dutta","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2016.07.014_b0240","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/47.5.505","article-title":"Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy","volume":"47","author":"Amaral","year":"2001","journal-title":"J. Antimicrob. Chemother."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116302971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116302971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T14:27:51Z","timestamp":1536589671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641116302971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":48,"alternative-id":["S0939641116302971"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2016.07.014","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2016.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}